Last reviewed · How we verify
PF-07976016 Formulation A (pf-07976016-formulation-a)
PF-07976016 Formulation A is a marketed drug by Pfizer Inc. It is used to treat Acute Ischemic Stroke, Ischemic Stroke, Migraine, Migraine Prevention, and Cluster Headache. The mechanism of action is not specified. PF-07976016 Formulation A has generated $63.6B in revenue. It has undergone 3 clinical trials and has 0 publications. This drug is a significant commercial entity in the pharmaceutical industry.
At a glance
| Generic name | pf-07976016-formulation-a |
|---|---|
| Sponsor | Pfizer |
| Drug class | Unknown |
| Target | Unknown |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Acute Ischemic Stroke
- Ischemic Stroke
- Migraine
- Migraine Prevention
- Cluster Headache
- Cluster Headache Prevention
- Hemicrania Continua
- Hemicrania Continua Prevention
- Chronic Cluster Headache
- Chronic Cluster Headache Prevention
- Chronic Hemicrania Continua
- Chronic Hemicrania Continua Prevention
- Chronic Migraine
- Chronic Migraine Prevention
- Chronic Cluster Headache with Aura
- Chronic Cluster Headache with Aura Prevention
- Chronic Hemicrania Continua with Aura
- Chronic Hemicrania Continua with Aura Prevention
- Chronic Migraine with Aura
- Chronic Migraine with Aura Prevention
Common side effects
Drug interactions
- Warfarin
- Aspirin
- Pentobarbital
- Phenobarbital
- Rivaroxaban
- Apixaban
- Dabigatran
- Clopidogrel
- Ticagrelor
- Prasugrel
- Abciximab
- Eptifibatide
Key clinical trials
- A Study to Learn How Different Forms of the Study Medicine Called PF-07976016 Are Taken Up Into the Blood in Healthy Adults (PHASE1)
- A Study to Understand How the Study Medicine (PF-07976016) is Processed and Eliminated in Healthy Men (PHASE1)
- A Study to Learn How Different Amounts of the Study Medicine Called PF-07976016 Are Tolerated and Act in The Body in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PF-07976016 Formulation A CI brief — competitive landscape report
- PF-07976016 Formulation A updates RSS · CI watch RSS
- Pfizer portfolio CI